# Chimagen Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chimagen-biosciences

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.chimagen.com
- Latest round: Series B (Nov 1, 2024)
- Investors on record: 2

## About

Chimagen Biosciences, based in Shanghai, China, specializes in developing innovative monoclonal antibodies targeting oncology, particularly colorectal cancer, utilizing cutting-edge immunotherapy techniques to address significant medical needs.Founded in 2016 in Shanghai, China, Chimagen Biosciences focuses on advancing multi-functional monoclonal antibodies for cancer treatments. The company has executed 5 deals, with their most recent deal occurring on November 1, 2024. The founder has a history of innovation in biosciences but specific details about prior companies are not disclosed.Chimagen Biosciences specializes in developing a new class of multi-functional monoclonal antibodies, with a primary focus on innovative therapies for oncology, particularly colorectal cancer. Their flagship product, CMG12, is a trispecific antibody designed to activate the immune system to target and eliminate cancer cells, addressing significant unmet medical needs in cancer treatment. The company's expertise spans from early discovery through clinical studies, partnering with leading research organizations and professionals in the immune-oncology sector to enhance the efficacy of their therapeutic offerings. Chimagen's products are primarily aimed at healthcare providers, research institutions, and pharmaceutical partners across global markets, targeting regions with advanced healthcare infrastructures and active oncology research programs.Chimagen Biosciences generates revenue through strategic partnerships and collaborations with research institutions and healthcare providers, focusing on B2B transactions. Their business model includes the potential for licensing agreements and joint ventures, allowing for shared development of their innovative monoclonal antibody products. The firm is committed to delivering effective cancer treatments, and its revenue structure is built around the commercialization of its flagship products, including CMG12, through partnerships with pharmaceutical companies and clinical research organizations. While specific pricing plans for their products and services are not publicly disclosed, the focus on effective therapeutic solutions positions Chimagen strategically within the biotech industry to negotiate favorable terms with partners and clients, further enhancing its market presence.In November 2024, Chimagen Biosciences raised an undisclosed amount in Series B funding from Foresite Capital and Lilly Asia Ventures. This funding will be utilized for new drug research and development and expanding their R&D pipeline. The company is also actively designing new products and aims to enter additional markets, particularly regions with robust oncology research initiatives, by mid-2025.

## Funding rounds

- Series B, Nov 1, 2024 — Lilly Asia Ventures, Foresite Capital

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B